RYTM (RYTM) Stock Analysis
Verdict: HOLD
IMCIVREE expansion drives 50%+ top-line growth, but high valuation (28.6x P/S) and deep net burn leave zero room for clinical slip-ups.
Investment score: 57/100
The model rates RYTM as a HOLD. While IMCIVREE commercial acceleration and pipeline readouts provide strong multi-year fundamentals, current valuation at 28.6x P/S reflects much of the near-term pipeline success.
Peers
| Peer | P/E | P/B | P/S | EV/EBITDA | ROIC % | Net margin % |
|---|---|---|---|---|---|---|
| CAI | 82.19 | 14.61 | 8.73 | 48.65 | — | 0.11 |
| IONS | -13.60 | 17.70 | 8.95 | 2.28 | — | -0.65 |
| IMVT | -13.16 | 10.37 | 1079.72 | -12.74 | — | -75.86 |
| CGON | -27.87 | 6.45 | 1065.73 | -29.81 | — | -36.03 |
| MIRM | -6.74 | -596.65 | 9.68 | -8.26 | — | -1.39 |